Population Pharmacokinetics of Atazanavir in Naïve HIV Infected Patients using Medication Events Monitoring System (MEMS) for drug intake timing

Size: px
Start display at page:

Download "Population Pharmacokinetics of Atazanavir in Naïve HIV Infected Patients using Medication Events Monitoring System (MEMS) for drug intake timing"

Transcription

1 Population Pharmacokinetics of Atazanavir in Naïve HIV Infected Patients using Medication Events Monitoring System (MEMS) for drug intake timing ANRS -COPHAR clinical trial Céline Verstuyft Pharmacologie, Université Paris Sud, CHU Bicêtre, On behalf of investigators (RM Savic, A Barrail-Tran, X Duval, G Nembot, X Panhard, D Descamps, B Vrijens, A-M Taburet, C Goujard, F Mentré and the ANRS COPHAR Study Group)

2 Rationale of the study ARVs exposure depends on: Pharmacokinetic parameters of a given drug Treatment adherence Adherence measure Pill count Self questionnaire MEMS -> exact timing of drug intake MEMS+PK-> optimization of drug concentrations and exposure Pharmacokinetics /pharmacogenetics of ATV analysis administered with ritonavir, using adherence rates as measured by MEMS

3 Oral Drug and interpatient variability PHENOTYPE D Dose Absorption Target Metabolism/ Elimination Polymorphism of transporter Polymorphism of target Polymorphism of enzyme (CYP) GENOTYPE

4 Patients and Method (I) Treatment naive HIV-infected patients (N=) for months ARV drugs : Reyataz (Atazanavir) ( mg) /ritonavir ( mg) Truvada (Emtricitabine/Tenofovir) In MEMS-capped bottles Sampling For drug assay Extensive PK at week post treatment initiation Through samples up to the end of study at weeks 8, and DNA for genetics of enzymes and transporters

5 Medication Event Monitoring System MEMS «Medication Event Monitoring System» Dosing Date Dosing Time 8 : : : 8: : N= N= Concentration of ATV and exact timing of drug intake

6 Material and method () ATV and RTV assayed by HPLC Pharmacogenetics study : Allelic discrimination / Taqman - Efflux transporters : MRP (rs77), MRP (rs7), MDR (rs) - Metabolism : CYPA (rs777), UGTA*8 (rs 877) - α Glycoprotein : ORM (A7G)

7 ATAZANAVIR CYPA CYPA*/* CYPA*/* Génotypes Frequencies (%) CYPA*/* Africans Caucasians Americans 8.. UGTA*8 CYPA CYPA UGTA CYPA*/* CYPA*/* Low Bioavaibility (Blanco et al., Pharmacogenetics, ) hepatic uptake: OAT, OATP, NTCP biliary excretion: MDR, BSEP, MRP, BCRP Ho R, Kim RB, Clin Pharm Ther, 7

8 Patients characteristics at baseline and clinical outcome Sex Masculin (N=9) Féminin (N=) Age Minimum = ans Médiane = ans Maximum = ans Mode de contamination Voie sexuelle (N=) Indéterminé (N=) HIV-RNA (cp/ml) Minimum= Médiane= Maximum= 7 Nbre de patients avec CV> = TCD+ (/mm ) Minimum= Médiane= 8 Maximum= patients with CD< = virological failures severe side events 8

9 Results (I) : Pharmacogenetics data Gene (rs number) CYPA (A98G) (rs 777) Genotype Number Phenotype * /* Higher expression * /* 7 Higher expression * /* No expression UGTA * /* Gain of function * /*8 *8 /*8 8 Lost of function MDR (CT) (rs ) CC Lower intracellular concentration CT TT 7 Higher intracellular concentration MRP (AG) (rs7) AA 9 Lower intracellular concentration AG GG Higher intracellular concentration MRP (rs77) (C-T) CC CT Higher Concentration TT ORM (A 7G ) AA AG GG 9

10 Results (II) : Atazanavir concentrations «lag-time»

11 Results (III) : Model selection : Several models investigated Transit compartments selected absorption Ke

12 FINAL MODEL FOR ALL OCCASIONS GOLD STANDARD ANALYSIS*: Parameter Estimate RSE (%) IIV (CV %) RSE (%) IOV (CV %) RSE (%) CL (L/h) <% NA V (L) ka (h-) MTT (h) NN.. *GOLD - standard data (MEMS data corrected for what has been reported RV S (%) 9.. in the patient diary) after that all samples which are unreliable has been excluded. RV, >S (%)..7 7 samples from patients samples excluded

13 Effect of CYPA polymorphism on ATV At least copy CYPA* allele CL/F +% And in ATV concentrations

14 Conclusion Le couplage des MEMS et des caractéristiques PK des ARV apporte une mesure de l exposition thérapeutique «globale», permettant d expliquer la réponse virologique L enregistrement des horaires de prise par les MEMS permet de corriger la variabilité individuelle des mesures de concentration des médicaments, et pourrait faciliter l adaptation des posologies Le MEMS est un nouvel outil, dont la place est à définir pour interpréter les données pharmacologiques dans le suivi des patients, en particulier dans les initiations de traitement (molécules nouvelles) ou les modifications chez les patients en échec

15 Acknowledgements Hopital Bicêtre : Pr C. Goujard Inserm U78 : F.Mentré, G.Nembot, X.Panhard, R. Savic Hopital Bichat : X.Duval (co-ip), D.Descamps Bicêtre : AM.Taburet, A.Barrail-Tran, A. Brunet AARDEX: B.Vrijjens Patients Investigators of clinical centers Pharmacists and pharmacologists BMS and Gilead for providing Reyataz and Truvada ANRS

CYP2B6 and NAT2 genetic polymorphisms enlighten the pharmacokinetic interaction of efavirenz with rifampicin and isoniazid - ANRS 12154 trial

CYP2B6 and NAT2 genetic polymorphisms enlighten the pharmacokinetic interaction of efavirenz with rifampicin and isoniazid - ANRS 12154 trial CYP2B6 and NAT2 genetic polymorphisms enlighten the pharmacokinetic interaction of efavirenz with rifampicin and isoniazid - ANRS 12154 trial Julie Bertrand 1,2, Céline Verstuyft 3,4, Monidarin Chou 5,

More information

Xavière Panhard and France Mentré. INSERM U738 - CHU Bichat Claude Bernard. Xavière Panhard - INSERM U738-16/06/05 p. 1

Xavière Panhard and France Mentré. INSERM U738 - CHU Bichat Claude Bernard. Xavière Panhard - INSERM U738-16/06/05 p. 1 Non-linear mixed-effects models for tests of interaction or of lack of interaction in cross-over and parallel pharmacokinetic studies: application to the test of interaction between protease inhibitors

More information

HCV Interaction Studies presented at the 15 th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, Washington, April 2014.

HCV Interaction Studies presented at the 15 th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, Washington, April 2014. Page 1 HCV Interaction Studies presented at the 15 th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, Washington, April 2014. This report summarises interaction studies relating

More information

EACS 2013. Dominique Braun Universitätsspital Zürich

EACS 2013. Dominique Braun Universitätsspital Zürich EACS 2013 Switch data Rilpivirine: Swing-trial Elvitegravir: Flamingo-trial Simplification Dual-Therapy: LPV/r + 3TC in the Gardel-trial Mono-Therapy: Darunavir/r mono in clinical setting Boceprevir/Telaprevir

More information

Understanding Pharmacokinetic Variability and Managing Drug Interactions

Understanding Pharmacokinetic Variability and Managing Drug Interactions Understanding Pharmacokinetic Variability and Managing Drug Interactions Courtney V. Fletcher, Pharm.D. Dean, College of Pharmacy Professor, Department of Pharmacy Practice and Division of Infectious Diseases

More information

Pharmacogenomics: an important step in the quest for biomarkers of drug response

Pharmacogenomics: an important step in the quest for biomarkers of drug response PHARMACOGENOMICS Development drugs/biologicals against completely new drug targets Pharmacogenomics: an important step in the quest for biomarkers of drug response Studying genetic variants as effect modifier

More information

Drug-Drug Interactions in the Treatment of Hepatitis C

Drug-Drug Interactions in the Treatment of Hepatitis C Drug-Drug Interactions in the Treatment of Hepatitis C Jennifer J. Kiser, PharmD University of Colorado Denver Department of Pharmaceutical Sciences May 11, 2013 Disclosures Jennifer Kiser receives or

More information

Liste d'adresses URL

Liste d'adresses URL Liste de sites Internet concernés dans l' étude Le 25/02/2014 Information à propos de contrefacon.fr Le site Internet https://www.contrefacon.fr/ permet de vérifier dans une base de donnée de plus d' 1

More information

5èmes journées du Site ANRS-Cameroun Yaoundé, 3-4 juin 2013 ANRS-12235

5èmes journées du Site ANRS-Cameroun Yaoundé, 3-4 juin 2013 ANRS-12235 èmes journées du Site ANRS-Cameroun Yaoundé, -4 juin 201 ANRS-122 Le sang total séché sur papier filtre, DBS (Dried Blood Spot), est-il utilisable pour le suivi virologique en routine des patients VIH+

More information

The question and answer session is not available after the live webinar.

The question and answer session is not available after the live webinar. 1 Read verbatim. 2 The Infectious Diseases Society of America (IDSA) Hepatitis C Knowledge Network offers monthly, 1 hour webinars to educate IDSA members on current recommended practices and treatments

More information

Personnalisez votre intérieur avec les revêtements imprimés ALYOS design

Personnalisez votre intérieur avec les revêtements imprimés ALYOS design Plafond tendu à froid ALYOS technology ALYOS technology vous propose un ensemble de solutions techniques pour vos intérieurs. Spécialiste dans le domaine du plafond tendu, nous avons conçu et développé

More information

Optimal dosing of warfarin in a pediatric cohort: height, INR target, VKORC1 and CYP2C9 genotypes are the main contributors of the dose requirement

Optimal dosing of warfarin in a pediatric cohort: height, INR target, VKORC1 and CYP2C9 genotypes are the main contributors of the dose requirement Optimal dosing of warfarin in a pediatric cohort: height, INR target, VKORC1 and CYP2C9 genotypes are the main contributors of the dose requirement Caroline Moreau et Fanny Bajolle JESFC 2012, Paris Introduction

More information

Interactions between Antiretrovirals and Drugs for Treatment of Pulmonary Arterial Hypertension

Interactions between Antiretrovirals and Drugs for Treatment of Pulmonary Arterial Hypertension Interactions between Antiretrovirals and Drugs for Treatment of Pulmonary Arterial Hypertension Protease Prostaglandin (prostacyclin) analogs Epoprostenol (IV) Undergoes rapid hydrolyzation Treprostinil

More information

Clinical Implementation of. Pharmacist-Managed Service. Kristine R. Crews, Pharm.D., BCPS St. Jude Children s Research Hospital

Clinical Implementation of. Pharmacist-Managed Service. Kristine R. Crews, Pharm.D., BCPS St. Jude Children s Research Hospital Clinical Implementation of Pharmacogenomics Through a Pharmacist-Managed Service Kristine R. Crews, Pharm.D., BCPS St. Jude Children s Research Hospital Objectives 1. Describe steps for incorporating pharmacogenomic

More information

Curriculum Vitae of Dr Michelle Viljoen

Curriculum Vitae of Dr Michelle Viljoen Curriculum Vitae of Dr Michelle Viljoen 1. General information Title, name and surname: Dr Michelle Viljoen Date of birth: 1970/08/29 Citizenship: RSA Professional registrations: SAPC- 0012959 2. Contact

More information

Meeting Report 15 th PK Workshop, Washington, 2014 Produced by www.hiv-druginteractions.org

Meeting Report 15 th PK Workshop, Washington, 2014 Produced by www.hiv-druginteractions.org Page 1 of 7 HIV Interaction Studies presented at the 15 th International Workshop on Clinical Pharmacology of HIV and HCV Therapy, Washington, April 2014. This report summarises interaction studies relating

More information

Régression logistique : introduction

Régression logistique : introduction Chapitre 16 Introduction à la statistique avec R Régression logistique : introduction Une variable à expliquer binaire Expliquer un risque suicidaire élevé en prison par La durée de la peine L existence

More information

Platelet Function Testing vs Genotyping : Focus on Pharmacogenomics of Clopidogrel. Kiyuk Chang, M.D., Ph.D.

Platelet Function Testing vs Genotyping : Focus on Pharmacogenomics of Clopidogrel. Kiyuk Chang, M.D., Ph.D. Platelet Function Testing vs Genotyping : Focus on Pharmacogenomics of Clopidogrel Kiyuk Chang, M.D., Ph.D. Cardiovascular Center & Cardiology Division Seoul St. Mary s Hospital The Catholic University

More information

Hepatitis C Treatment of Active IV Drug Users Tania Dunn, RN Isabelle Gendron, RN B.Sc.

Hepatitis C Treatment of Active IV Drug Users Tania Dunn, RN Isabelle Gendron, RN B.Sc. Hepatitis C Treatment of Active IV Drug Users Tania Dunn, RN Isabelle Gendron, RN B.Sc. CRD Le Virage Équipe TDO GMF de l UMF Charles LeMoyne St-Lambert, Quebec February 2012 Potential Conflicts of Interest

More information

Lessons from the Stanford HIV Drug Resistance Database

Lessons from the Stanford HIV Drug Resistance Database 1 Lessons from the Stanford HIV Drug Resistance Database Bob Shafer, MD Department of Medicine and by Courtesy Pathology (Infectious Diseases) Stanford University Outline 2 Goals and rationale for HIVDB

More information

Rapid HCP5 single-nucleotide polymorphism genotyping: a simple allele-specific PCR method for prediction of hypersensitivity reaction to Abacavir.

Rapid HCP5 single-nucleotide polymorphism genotyping: a simple allele-specific PCR method for prediction of hypersensitivity reaction to Abacavir. A simple allele-specific polymerase chain reaction method to detect the Gly143Glu polymorphism in the human carboxylesterase 1 gene: importance of genotyping for pharmacogenetic treatment. Walter Soria

More information

Robert G. Knodell, M.D. Maryland Chapter, American College of Physicians Fb February 3, 2012

Robert G. Knodell, M.D. Maryland Chapter, American College of Physicians Fb February 3, 2012 Treatment of Hepatitis C:Present and Future Robert G. Knodell, M.D. Scientific Meeting Maryland Chapter, American College of Physicians Fb February 3, 2012 Presentation Objectives Appreciate the Public

More information

BRIVARACETAM. Paediatric Development in Partial Onset Seizures. 17 May 2016 HQ/0516/BRV/00022

BRIVARACETAM. Paediatric Development in Partial Onset Seizures. 17 May 2016 HQ/0516/BRV/00022 BRIVARACETAM Paediatric Development in Partial Onset Seizures 17 May 2016 HQ/0516/BRV/00022 Brivaracetam is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary

More information

Safety and Efficacy of DAA + PR in HCV/HIV co-infected patients. Mark Sulkowski, MD Johns Hopkins University Baltimore Maryland USA

Safety and Efficacy of DAA + PR in HCV/HIV co-infected patients. Mark Sulkowski, MD Johns Hopkins University Baltimore Maryland USA Safety and Efficacy of DAA + PR in HCV/HIV co-infected patients Mark Sulkowski, MD Johns Hopkins University Baltimore Maryland USA Liver disease is the second leading cause of death amongst HIV-positive

More information

HEPATITIS WEB STUDY Acute Hepatitis C Virus Infection: Epidemiology, Clinical Features, and Diagnosis

HEPATITIS WEB STUDY Acute Hepatitis C Virus Infection: Epidemiology, Clinical Features, and Diagnosis HEPATITIS WEB STUDY Acute C Virus Infection: Epidemiology, Clinical Features, and Diagnosis H. Nina Kim, MD Assistant Professor of Medicine Division of Infectious Diseases University of Washington School

More information

London Therapeutic Tender Implementation: Guidance for Clinical Use. 4 th June 2014 FINAL

London Therapeutic Tender Implementation: Guidance for Clinical Use. 4 th June 2014 FINAL London Therapeutic Tender Implementation: Guidance for Clinical Use 4 th June 2014 FINAL Contents 3. General principles 4. Financial impact of therapeutic tendering for branded ARVs 5. London ARV algorithm:

More information

Pharmacogenetic Activities in SWOG Breast Cancer

Pharmacogenetic Activities in SWOG Breast Cancer Pharmacogenetic Activities in SWOG Breast Cancer Pharmacogenomics: Future Plans S8897 Adjuvant CMF vs. CAF/ no Treatment Ambrosone RO1: Other genes (TBCI approved, analyses ongoing) S0221 Adjuvant Dose

More information

Guideline on the investigation of drug interactions

Guideline on the investigation of drug interactions 21 June 2012 CPMP/EWP/560/95/Rev. 1 Corr. 2** Committee for Human Medicinal Products (CHMP) Discussion in the Efficacy Working Party (EWP) June/October 1996 February 1997 Transmission to the CPMP March

More information

Introduction. GEAL Bibliothèque Java pour écrire des algorithmes évolutionnaires. Objectifs. Simplicité Evolution et coévolution Parallélisme

Introduction. GEAL Bibliothèque Java pour écrire des algorithmes évolutionnaires. Objectifs. Simplicité Evolution et coévolution Parallélisme GEAL 1.2 Generic Evolutionary Algorithm Library http://dpt-info.u-strasbg.fr/~blansche/fr/geal.html 1 /38 Introduction GEAL Bibliothèque Java pour écrire des algorithmes évolutionnaires Objectifs Généricité

More information

When should in vivo transportermediated drug-drug interaction studies be conducted? A scientific perspective

When should in vivo transportermediated drug-drug interaction studies be conducted? A scientific perspective Science at Sunrise, March 7, 2015 When should in vivo transportermediated drug-drug interaction studies be conducted? A scientific perspective Lei Zhang, Ph.D. Office of Clinical Pharmacology Office of

More information

ASTHMA. Kaitlin Atkinson Family Resource Library Resource List. Follow @CHEOfrl Follow @CHEOhospital

ASTHMA. Kaitlin Atkinson Family Resource Library Resource List. Follow @CHEOfrl Follow @CHEOhospital ASTHMA Kaitlin Atkinson Family Resource Library Resource List Follow @CHEOfrl Follow @CHEOhospital General Information and Resources for Parents 100 questions & answers about your child's asthma / Plottel,

More information

New anticoagulants: Monitoring or not Monitoring? Not Monitoring

New anticoagulants: Monitoring or not Monitoring? Not Monitoring The 2 nd World Congress on CONTROVERSIES IN HEMATOLOGY (COHEM) Barcelona, Spain September 6 8, 2012 New anticoagulants: Monitoring or not Monitoring? Not Monitoring Anna Falanga, MD Immunohematology and

More information

HARVONI (ledipasvir and sofosbuvir) tablets, for oral use Initial U.S. Approval: 2014

HARVONI (ledipasvir and sofosbuvir) tablets, for oral use Initial U.S. Approval: 2014 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use HARVONI safely and effectively. See full prescribing information for HARVONI. HARVONI (ledipasvir

More information

The Basics of Drug Resistance:

The Basics of Drug Resistance: CONTACT: Lisa Rossi +1-412-641-8940 +1-412- 916-3315 (mobile) rossil@upmc.edu The Basics of Drug Resistance: QUESTIONS AND ANSWERS HIV Drug Resistance and ARV-Based Prevention 1. What is drug resistance?

More information

«Object-Oriented Multi-Methods in Cecil» Craig Chambers (Cours IFT6310, H08)

«Object-Oriented Multi-Methods in Cecil» Craig Chambers (Cours IFT6310, H08) «Object-Oriented Multi-Methods in Cecil» Craig Chambers (Cours IFT6310, H08) Mathieu Lemoine 2008/02/25 Craig Chambers : Professeur à l Université de Washington au département de Computer Science and Engineering,

More information

SUMMARY OF CHANGES INCLUDED IN THE FULL PROTOCOL AMENDMENT OF:

SUMMARY OF CHANGES INCLUDED IN THE FULL PROTOCOL AMENDMENT OF: SUMMARY OF CHANGES INCLUDED IN THE FULL PROTOCOL AMENDMENT OF: IMPAACT P1026s Pharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy and Postpartum (DAIDS Document ID 10040) IND

More information

Helen McIlleron 2, Concepta Merry 1, Pete Smith 2, Gary Maartens 2. Trinity College, Dublin, Ireland. University of Cape Town, South Africa

Helen McIlleron 2, Concepta Merry 1, Pete Smith 2, Gary Maartens 2. Trinity College, Dublin, Ireland. University of Cape Town, South Africa EDCTP 4th annual forum. Building Bridges for Better Health 22 to 24 October 2007, Ouagadougou, Burkina Faso Determining the optimal doses of antiretroviral and antituberculous medications when used in

More information

HIV/HCV Co-Infection

HIV/HCV Co-Infection HIV/HCV Co-Infection 2015 Kentucky Conference on Viral Hepatitis Matt Cave, M.D. Associate Professor Department of Medicine Division of Gastroenterology, Hepatology, & Nutrition Department of Pharmacology

More information

MM Thorell PhD University of the Sciences in Philadelphia, 600 South 43rd Street, Philadelphia, Pennsylvania, , USA.

MM Thorell PhD University of the Sciences in Philadelphia, 600 South 43rd Street, Philadelphia, Pennsylvania, , USA. Medical Journal of Therapeutics Africa 2007 Vol 1, No 2 Page 148 SUMMARY OF GUIDELINES FOR THE USE OF ANTIRETROVIRAL AGENTS IN HIV-INFECTED ADULTS AND ADOLESCENTS. MM Thorell PhD University of the Sciences

More information

Account Manager H/F - CDI - France

Account Manager H/F - CDI - France Account Manager H/F - CDI - France La société Fondée en 2007, Dolead est un acteur majeur et innovant dans l univers de la publicité sur Internet. En 2013, Dolead a réalisé un chiffre d affaires de près

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Drug Interaction Studies Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations DRAFT GUIDANCE This guidance document is being distributed for comment

More information

Management of HIV and TB Co-infection in South Africa

Management of HIV and TB Co-infection in South Africa Management of HIV and TB Co-infection in South Africa Halima Dawood Department of Medicine Case Report 39 yr old female Referred to clinic on 14/06/2006 for consideration to commence antiretroviral therapy

More information

Drug-Drug Interactions in TB-Diabetes and HIV-TB

Drug-Drug Interactions in TB-Diabetes and HIV-TB Drug-Drug Interactions in TB-Diabetes and HIV-TB 11 May 2016 Developing a Comprehensive Therapeutic Research Strategy for the Converging Epidemics of TB, T2DM, and HIV Workshop NIAID, NIDDK, Office of

More information

Introduction au BIM. ESEB 38170 Seyssinet-Pariset Economie de la construction email : contact@eseb.fr

Introduction au BIM. ESEB 38170 Seyssinet-Pariset Economie de la construction email : contact@eseb.fr Quel est l objectif? 1 La France n est pas le seul pays impliqué 2 Une démarche obligatoire 3 Une organisation plus efficace 4 Le contexte 5 Risque d erreur INTERVENANTS : - Architecte - Économiste - Contrôleur

More information

Troncatures dans les modèles linéaires simples et à effets mixtes sous R

Troncatures dans les modèles linéaires simples et à effets mixtes sous R Troncatures dans les modèles linéaires simples et à effets mixtes sous R Lyon, 27 et 28 juin 2013 D.Thiam, J.C Thalabard, G.Nuel Université Paris Descartes MAP5 UMR CNRS 8145 IRD UMR 216 2èmes Rencontres

More information

HIV Pre-Exposure Prophylaxis (PrEP): A brief guide for providers updated January 2016

HIV Pre-Exposure Prophylaxis (PrEP): A brief guide for providers updated January 2016 HIV Pre-Exposure Prophylaxis (PrEP): A brief guide for providers updated January 2016 Daily emtricitabine/tenofovir (Truvada ) is safe and effective for reducing the risk of HIV acquisition in sexually

More information

Clinical Implementation of Psychiatric Pharmacogenomic Testing

Clinical Implementation of Psychiatric Pharmacogenomic Testing Clinical Implementation of Psychiatric Pharmacogenomic Testing David A. Mrazek, M.D., F.R.C.Psych. Mayo Clinic Characterizing and Displaying Genetic Variants for Clinical Action December 2, 2011 Relationships

More information

Opioid Prescribing for Chronic Pain: Guidelines for Marin County Clinicians

Opioid Prescribing for Chronic Pain: Guidelines for Marin County Clinicians Opioid Prescribing for Chronic Pain: Guidelines for Marin County Clinicians Although prescription pain medications are intended to improve the lives of people with pain, their increased use and misuse

More information

Medication Utilization. Understanding Potential Medication Problems of the Elderly

Medication Utilization. Understanding Potential Medication Problems of the Elderly Medication Utilization Understanding Potential Medication Problems of the Elderly NICE - National Initiative for the Care of the Elderly WHAT ARE MEDICATION UTILIZATION PROBLEMS AMONG THE ELDERLY? A useful

More information

N.C Talam 1, P. Gatongi 2, J. Rotich 3 ; S. Kimaiyo 4. Abstract

N.C Talam 1, P. Gatongi 2, J. Rotich 3 ; S. Kimaiyo 4. Abstract 74 FACTORS AFFECTING ANTIRETROVIRAL DRUG ADHERENCE AMONG HIV/AIDS ADULT PATIENTS ATTENDING HIV/AIDS CLINIC AT MOI TEACHING AND REFERRAL HOSPITAL, ELDORET, KENYA. Abstract N.C Talam 1, P. Gatongi 2, J.

More information

Hepatitis Update. Study 110: SVR at post-treatment week 24 (SVR24) Jürgen Rockstroh, MD. No ART EFV/TDF/FTC ART/r/TDF/FTC Total

Hepatitis Update. Study 110: SVR at post-treatment week 24 (SVR24) Jürgen Rockstroh, MD. No ART EFV/TDF/FTC ART/r/TDF/FTC Total Hepatitis Update Jürgen Rockstroh, MD Study 11: SVR at post-treatment week 24 (SVR24) Patients with Undetectable HCV RNA (Percentage) 8 7 6 5 4 3 2 1 71 No ART EFV/TDF/FTC ART/r/TDF/FTC Total 69 8 74 n/n

More information

QUALITY AND SAFETY TESTING

QUALITY AND SAFETY TESTING QUALITY AND SAFETY TESTING Large scale of solutions for the identification and rapid detection of micro-organisms. Easier investment in molecular techniques Frédéric BAR, Key Account Manager b2 b3b4 Quality

More information

Spectrométrie d absorption moléculaire UV-visible

Spectrométrie d absorption moléculaire UV-visible Spectrométrie d absorption moléculaire 1 faibles quantités échantillon liquide byfiles.storage.live.com/y1php6mrdyehuw8p4jw0... non destructrice bp0.blogger.com/.../m_7spgk78eu/s400/boum_4.png s'applique

More information

in HIV/HCV-Coinfected Patients: role of the HCV sustained viral suppression

in HIV/HCV-Coinfected Patients: role of the HCV sustained viral suppression M42-Determinants M19 of HIV Sustained Viral Suppression in HIV/HCV-Coinfected Patients: role of the HCV sustained viral suppression F. Bani-Sadr 1-2, M-A Loko 2, E. Pambrun 2, M. Winnock 2, P. Carrieri

More information

Viral load testing. medical monitoring: viral load testing: 1

Viral load testing. medical monitoring: viral load testing: 1 medical monitoring: viral load testing: 1 medical monitoring: viral load testing Viral load testing medical monitoring: viral load testing: 2 Slide 1 Viral load The viral load test measures HIV in the

More information

Another way to look at the Project Une autre manière de regarder le projet. Montpellier 23 juin - 4 juillet 2008 Gourlot J.-P.

Another way to look at the Project Une autre manière de regarder le projet. Montpellier 23 juin - 4 juillet 2008 Gourlot J.-P. Another way to look at the Project Une autre manière de regarder le projet Montpellier 23 juin - 4 juillet 2008 Gourlot J.-P. Plan of presentation Plan de présentation Introduction Components C, D The

More information

Le nuove sfide dell HIV

Le nuove sfide dell HIV Le nuove sfide dell HIV Caso clinico Un paziente altoviremico Giuseppina Liuzzi Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani Caso clinico(1) In data 29.10.15 Donna in gravidanza 19a

More information

M1 UE3 Examen final 2014 / 2015 : China infrastructures strategy

M1 UE3 Examen final 2014 / 2015 : China infrastructures strategy UE3 : Marchés internationaux Amonts M1 UE3 Examen final 2014 / 2015 : China infrastructures strategy Pascal ALBERTINI 14/05/2015 L7N 1 China Infrastructures Strategy Vous, Patrick KRON, Président d Alstom,

More information

AgroMarketDay. Research Application Summary pp: 371-375. Abstract

AgroMarketDay. Research Application Summary pp: 371-375. Abstract Fourth RUFORUM Biennial Regional Conference 21-25 July 2014, Maputo, Mozambique 371 Research Application Summary pp: 371-375 AgroMarketDay Katusiime, L. 1 & Omiat, I. 1 1 Kampala, Uganda Corresponding

More information

Drug drug interaction of new HCV drugs

Drug drug interaction of new HCV drugs Drug drug interaction of new HCV drugs Stefano Bonora University of Torino Disposition of old DAAs Drug Dosing regimen CYP P-glycoprotein Non-CYP metabolism Telaprevir Q8h No significant boosting by RTV

More information

HIV Drug Resistance in the Asia- Pacific

HIV Drug Resistance in the Asia- Pacific HIV Drug Resistance in the Asia- Pacific David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia HIVDR in Asia Pacific Transmitted resistance

More information

Herta Crauwels, et al.: Rilpivirine Drug-Drug Interactions

Herta Crauwels, et al.: Rilpivirine Drug-Drug Interactions AIDS Rev. 2013;15:87 101 Herta Crauwels, et al.: Rilpivirine Drug-Drug Interactions Clinical Perspective on Drug Drug Interactions with the Non-nucleoside Reverse Transcriptase Inhibitor Rilpivirine Herta

More information

Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey.

Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey. Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey. Céline Dartois, Karl Brendel, Emmanuelle Comets, Céline Laffont, Christian Laveille, Brigitte Tranchand,

More information

Getting to Know PrEP (Pre-Exposure Prophylaxis)

Getting to Know PrEP (Pre-Exposure Prophylaxis) (Pre-Exposure Prophylaxis) What is PrEP? Prep stands for Pre-Exposure Prophylaxis: a medication that was recently approved by the FDA for daily use that can help high-risk patients who are HIV negative

More information

LA TERAPIA PER HBV ed HCV Differenze di Genere? Alfredo Alberti. Dipartimento di Medicina Molecolare UOC Medicina Generale VIMM Università di Padova

LA TERAPIA PER HBV ed HCV Differenze di Genere? Alfredo Alberti. Dipartimento di Medicina Molecolare UOC Medicina Generale VIMM Università di Padova LA TERAPIA PER HBV ed HCV Differenze di Genere? Alfredo Alberti Dipartimento di Medicina Molecolare UOC Medicina Generale VIMM Università di Padova HBV ed HCV Due virus Diversi ma con molte Cose in Comune

More information

HIV TREATMENT ADHERENCE

HIV TREATMENT ADHERENCE Australian Federation of AIDS Organisations PO Box 51 Newtown NSW 2042 www.afao.org.au July 2009 Information on adherence and hints to help manage your HIV medications HIV TREATMENT ADHERENCE What is adherence?

More information

Generic antiretrovirals in Europe: a blessing or a curse?

Generic antiretrovirals in Europe: a blessing or a curse? Generic antiretrovirals in Europe: a blessing or a curse? Ricardo Jorge Camacho 1 Molecular Biology Laboratory, Centro Hospitalar de Lisboa Ocidental 2 Instituto de Higiene e Medicina Tropical, Universidade

More information

Safety of Nucleos(t)ide Analogues during Long-Term Treatment of Chronic Hepatitis B

Safety of Nucleos(t)ide Analogues during Long-Term Treatment of Chronic Hepatitis B Safety of Nucleos(t)ide Analogues during Long-Term Treatment of Chronic Hepatitis B Anna S. F. Lok, MD Alice Lohrman Andrews Research Professor in Hepatology Director of Clinical Hepatology University

More information

Thursday, February 7, 2013. DOM via PHP

Thursday, February 7, 2013. DOM via PHP DOM via PHP Plan PHP DOM PHP : Hypertext Preprocessor Langage de script pour création de pages Web dynamiques Un ficher PHP est un ficher HTML avec du code PHP

More information

REQUEST FORM FORMULAIRE DE REQUÊTE

REQUEST FORM FORMULAIRE DE REQUÊTE REQUEST FORM FORMULAIRE DE REQUÊTE ON THE BASIS OF THIS REQUEST FORM, AND PROVIDED THE INTERVENTION IS ELIGIBLE, THE PROJECT MANAGEMENT UNIT WILL DISCUSS WITH YOU THE DRAFTING OF THE TERMS OF REFERENCES

More information

Clinical Criteria for Hepatitis C (HCV) Therapy

Clinical Criteria for Hepatitis C (HCV) Therapy Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C (HCV infection > 6 months), genotype and sub-genotype specified to determine the length of therapy; Liver biopsy

More information

HCV/HIVCo-infection A case study by. Dominic Côté, Nurse Clinician B.Sc Chronic Viral Illness Services McGill University Health Centre

HCV/HIVCo-infection A case study by. Dominic Côté, Nurse Clinician B.Sc Chronic Viral Illness Services McGill University Health Centre HCV/HIVCo-infection A case study by Dominic Côté, Nurse Clinician B.Sc Chronic Viral Illness Services McGill University Health Centre Objectives By sharing a case study of a patient co-infected with HIV/HCV

More information

Antiretroviral Treatment Options for Patients on Directly Acting Antivirals for Hepatitis C. Daclatasvir (Daklinza, DCV, BMS-790052)

Antiretroviral Treatment Options for Patients on Directly Acting Antivirals for Hepatitis C. Daclatasvir (Daklinza, DCV, BMS-790052) Antiretroviral Treatment Options for Patients on Directly Acting Antivirals for Hepatitis C PIs: atazanavir PIs: other Simeprevir with ritonavir- or cobicistat boosted PIs (significant simeprevir AUC).

More information

Didactic Series. Updated Post-Exposure Prophylaxis (PEP) Guidelines. Daniel Lee, MD UCSD Medical Center, Owen Clinic January 9, 2014

Didactic Series. Updated Post-Exposure Prophylaxis (PEP) Guidelines. Daniel Lee, MD UCSD Medical Center, Owen Clinic January 9, 2014 Didactic Series Updated Post-Exposure Prophylaxis (PEP) Guidelines Daniel Lee, MD UCSD Medical Center, Owen Clinic January 9, 2014 ACCREDITATION STATEMENT: University of California, San Diego School of

More information

Treating HIV in children with tuberculosis

Treating HIV in children with tuberculosis International AIDS Society - Industry Liaison Forum Meeting 5 March 2012 Treating HIV in children with tuberculosis Helen McIlleron, Division of Clinical Pharmacology University of Cape Town Challenges

More information

Routine HIV Monitoring

Routine HIV Monitoring Routine HIV Monitoring Guideline of the HIV/AIDS Division at San Francisco General Hospital Statement of Guideline: Patients will be routinely evaluated and monitored for HIV parameters, antiretroviral

More information

Audit de sécurité avec Backtrack 5

Audit de sécurité avec Backtrack 5 Audit de sécurité avec Backtrack 5 DUMITRESCU Andrei EL RAOUSTI Habib Université de Versailles Saint-Quentin-En-Yvelines 24-05-2012 UVSQ - Audit de sécurité avec Backtrack 5 DUMITRESCU Andrei EL RAOUSTI

More information

Interactions Between Antiretrovirals and Antiplatelet Agents and Novel Oral Anticoagulants

Interactions Between Antiretrovirals and Antiplatelet Agents and Novel Oral Anticoagulants Dosing Metabolism Clopidogrel (Plavix ) 300mg 600mg loading dose 75 mg daily maintenance dose Prodrug activated by CYP2C19 (major), CYP2B6 & metabolism. CYP2B6. 1 Prasugrel (Effient ) 60mg loading dose

More information

Enterprise Data Center A c h itec tu re Consorzio Operativo Gruppo MPS Case S t u d y : P r o g et t o D i sast er R ec o v er y Milano, 7 Febbraio 2006 1 Il G r u p p o M P S L a B a n c a M o n t e d

More information

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY Original Issue Date (Created): 4/1/2012 Most Recent Review Date (Revised): 7/26/2016 Effective Date: 11/23/2016 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS

More information

Benin Business visa Application

Benin Business visa Application Benin Business visa Application Please enter your contact information Name: Email: Tel: Mobile: The latest date you need your passport returned in time for your travel: Benin business visa checklist Filled

More information

Introduction ToIP/Asterisk Quelques applications Trixbox/FOP Autres distributions Conclusion. Asterisk et la ToIP. Projet tuteuré

Introduction ToIP/Asterisk Quelques applications Trixbox/FOP Autres distributions Conclusion. Asterisk et la ToIP. Projet tuteuré Asterisk et la ToIP Projet tuteuré Luis Alonso Domínguez López, Romain Gegout, Quentin Hourlier, Benoit Henryon IUT Charlemagne, Licence ASRALL 2008-2009 31 mars 2009 Asterisk et la ToIP 31 mars 2009 1

More information

Correlation of Drug Levels and Outcomes in Phase III New Oral Anticoagulant (NOAC) Trials

Correlation of Drug Levels and Outcomes in Phase III New Oral Anticoagulant (NOAC) Trials Correlation of Drug Levels and Outcomes in Phase III New Oral Anticoagulant (NOAC) Trials October 26, 2015 CDER/OTS/OCP/DPM Jeffry Florian, Ph.D. CDER/OND/ODE1/DCRP Martin Rose, M.D. 1 Outline Overview

More information

NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS (npep)

NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS (npep) NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS (npep) Guidance from the Michigan Department of Health and Human Services Division of Health, Wellness & Disease Control Revised June 2015 The Michigan Department

More information

Guidance for Industry

Guidance for Industry Guidance for Industry End-of-Phase 2A Meetings U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) September 2009 Procedural Guidance

More information

PKPD modelling of the relationship between testosterone and PSA in patients with prostate cancer during treatment with leuprorelin

PKPD modelling of the relationship between testosterone and PSA in patients with prostate cancer during treatment with leuprorelin PAGE 2015, Crete PKPD modelling of the relationship between testosterone and PSA in patients with prostate cancer during treatment with leuprorelin What is the optimal testosterone level? Nelleke Snelder,

More information

treatments) worked by killing cancerous cells using chemo or radiotherapy. While these techniques can

treatments) worked by killing cancerous cells using chemo or radiotherapy. While these techniques can Shristi Pandey Genomics and Medicine Winter 2011 Prof. Doug Brutlag Chronic Myeloid Leukemia: A look into how genomics is changing the way we treat Cancer. Until the late 1990s, nearly all treatment methods

More information

Victrelis: hints for success. Katarnya Gilbert Hepatology MSL MSD

Victrelis: hints for success. Katarnya Gilbert Hepatology MSL MSD Victrelis: hints for success Katarnya Gilbert Hepatology MSL MSD 1 Some Facts: BOC has no clinically significant activity against other HCV genotypes. Resistance with protease inhibitor monotherapy can

More information

GSAC CONSIGNE DE NAVIGABILITE définie par la DIRECTION GENERALE DE L AVIATION CIVILE Les examens ou modifications décrits ci-dessous sont impératifs. La non application des exigences contenues dans cette

More information

Bac + 04 Licence en science commerciale, option marketing et communication. Degree in computer science, engineering or equivalent

Bac + 04 Licence en science commerciale, option marketing et communication. Degree in computer science, engineering or equivalent L un de ces postes vous intéresse? Postulez sur djezzy@talents-network.com Communication Brand senior manager Bac + 04 Licence en science commerciale, option marketing et communication. 05 years minimum

More information

Travaux publics et Services gouvernementaux Canada. Title - Sujet LEARNING SERVICES. Solicitation No. - N de l'invitation E60ZH-070003

Travaux publics et Services gouvernementaux Canada. Title - Sujet LEARNING SERVICES. Solicitation No. - N de l'invitation E60ZH-070003 Public Works and Government Canada RETURN BIDS TO: RETOURNER LES SOUMISSIONS À: Bid Receiving - PWGSC / Réception des soumissions - TPSGC 11 Laurier St. / 11, rue Laurier Place du Portage, Phase III Core

More information

RLC/MAC Uplink Transfer

RLC/MAC Uplink Transfer FORMATION GPRS - TD SIB RLC/MAC Uplink Transfer Access procedure: one phase access CHANNEL REQUEST One Phase Access IMMEDIATE ASSIGNMENT Request Reference / PDCH description / TBF parameters IMMEDIATE_ASSIGNMENT

More information

REQUEST FORM FORMULAIRE DE REQUÊTE

REQUEST FORM FORMULAIRE DE REQUÊTE REQUEST FORM FORMULAIRE DE REQUÊTE ON THE BASIS OF THIS REQUEST FORM, AND PROVIDED THE INTERVENTION IS ELIGIBLE, THE PROJECT MANAGEMENT UNIT WILL DISCUSS WITH YOU THE DRAFTING OF THE TERMS OF REFERENCES

More information

Implementation of Pharmacogenomics in Clinical Practice: Barriers and Potential Solutions

Implementation of Pharmacogenomics in Clinical Practice: Barriers and Potential Solutions Molecular Pathology : Principles in Clinical Practice Implementation of Pharmacogenomics in Clinical Practice: Barriers and Potential Solutions KT Jerry Yeo, Ph.D. University of Chicago Email: jyeo@bsd.uchicago.edu

More information

Interface of Different Modules Within Simcyp

Interface of Different Modules Within Simcyp Data Entry & Input Interface of Different Modules Within Simcyp Flexibility for Variable Input & Added Complexity Compound Parameters Library Parameters LIVER GI TRACT KIDNEY 1. Whole Organ Clearance MPPGL

More information

Statistiques en grande dimension

Statistiques en grande dimension Statistiques en grande dimension Christophe Giraud 1,2 et Tristan Mary-Huart 3,4 (1) Université Paris-Sud (2) Ecole Polytechnique (3) AgroParistech (4) INRA - Le Moulon M2 MathSV & Maths Aléa C. Giraud

More information

Preamble. Introduction. Marc G. Ghany, 1 David R. Nelson, 2 Doris B. Strader, 3 David L. Thomas, 4 and Leonard B. Seeff 5 *

Preamble. Introduction. Marc G. Ghany, 1 David R. Nelson, 2 Doris B. Strader, 3 David L. Thomas, 4 and Leonard B. Seeff 5 * An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases A new section on Use and Interpretation of

More information

Drug-Drug Interactions

Drug-Drug Interactions Slide 1 Drug-Drug Interactions David Back University of Liverpool UK David Back University of Liverpool C-Hep Berlin October 2012 Interactions with the new HepC drugs are challenging! Slide 2 Number of

More information

Outsourcing in Drug Development From the Bench to the Market. Steven A. Kates, PhD Ischemix LLC

Outsourcing in Drug Development From the Bench to the Market. Steven A. Kates, PhD Ischemix LLC Outsourcing in Drug Development From the Bench to the Market Steven A. Kates, PhD Ischemix LLC Ischemix LLC 2012 Introduction Drug Development Process Ischemix LLC 2012 2 Introduction Drug Development

More information

Update on Hepatitis C. Sally Williams MD

Update on Hepatitis C. Sally Williams MD Update on Hepatitis C Sally Williams MD Hep C is Everywhere! Hepatitis C Magnitude of the Infection Probably 8 to 10 million people in the U.S. are infected with Hep C 30,000 new cases are diagnosed annually;

More information